ClinicalTrials.gg
CompletedNCT04712500Updated May 11, 2021

A Food-Effect Study of AND017 in Healthy Participants

A Phase 1 interventional study of AND017 in Healthy Volunteers, sponsored by Kind Pharmaceuticals LLC. Completed at 1 site in China. Open to participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2021-05-11.

Sponsored by Kind Pharmaceuticals LLC · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Registered 5 months after the study started (first participant enrolled Jul 2020, registered Jan 2021).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
14
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
All
01

Study summary

The purpose of this phase I study is to evaluate the food effect on the PKs of AND017 following oral single-dose administration in healthy non-elderly Chinese subjects.

Read the detailed description

This is a single-center, randomized, open-label, two-sequence, two-period crossover study in healthy non-elderly Chinese subjects to evaluate the food effect on the pharmacokinetics, as well as PD and safety of AND017 following oral single-dose administration

02

Conditions studied

  • Healthy Volunteers
03

In context

Lead sponsor

Kind Pharmaceuticals LLC is the lead sponsor of 11 studies on the registry; 7 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. between 19.0\~26.0 kg/m2 (both inclusive); Body weight ≥50 kg for male, and ≥45 kg for female.
  2. Healthy participants having no clinical significant abnormalities of examinations during screening period and at the time of
  3. Have no pregnancy plan in the next six months and are willing to take effective methods.

Exclusion criteria

Exclusion Criteria:

  1. Allergic constitution or has a history of allergy to AND017 capsule and its ;
  2. Subjects with low blood pressure or a risk of low blood pressure: systolic pressure \<90 mmHg, diastolic pressure\<60 mmHg.
  3. Subjects with difficulty in venous blood sampling;
  4. Subjects with a history of drug abuse within the past five years or who have abused drug within the past three months before screening;
  5. Subjects smoking more than five cigarettes a day or nicotine dependent within the past three months before screening;
  6. Subjects drinking alcohol more than 14 U/week within the past six months or used any alcohol products in two days pre-dose;
  7. Subjects that have received any medication within the past 4 weeks pre-dose;
  8. Subjects that have taken food or drink that has the potential to induce or inhibit drug metabolizing enzymes in the liver within one-week pre-dose;
  9. Subjects that have taken any food or drink that contains or can be metabolized to caffeine or xanthine from 48 hours pre-dose to the last PK or PD blood sampling;
  10. Subjects with diseases or factors of clinical abnormalities that need to be excluded, including but not limited to the nervous system, cardiovascular system, kidney, liver, gastrointestinal, respiratory system, metabolism, and skeletal system diseases, or other factors that may affect drug absorption, distribution, metabolism and excretion;
  11. Subjects that have used HIF-PHIs within the past one year;
  12. Subjects positive in -Ab, or HBeAg, or -Ab, TP-Ab;
  13. Subjects that have participated in any other clinical trials within the past three months pre-dose in the study;
  14. Female subjects of childbearing age who are pregnant, lactating, or planning pregnancy; or have a positive in pregnancy test during the study;
  15. Subjects with a history of blood donation or had a blood loss more than 400 mL within three months before screening;
  16. Subjects that have special requirements on diet and cannot follow the dietary program indicated in the study;
  17. Subjects that are unable to comply with research requirements or with any factors are considered not suitable for participating in the study according to the opinion of the investigator.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
14 participants (actual)

Study arms

  • Experimental
    AND017: Fasted - Fed

    Subjects were randomized to receive single dose of AND017 under fasted condition in Period 1 and under fed condition in Period 2

    Drug: AND017

  • Experimental
    AND017: Fed - Fasted

    Subjects were randomized to receive single dose of AND017 under fed condition in Period 1 and under fasted condition in Period 2

    Drug: AND017

Interventions

06

What researchers measure

Primary outcomes

  1. Cmax

    Maximum Observed Plasma Concentration for AND017

    Time frame: Day 1 and Day 6, 0-72 hours post-dose

  2. AUC0-inf

    Area Under the Plasma Concentration-time Curve from Time 0 to Infinite Time for AND017

    Time frame: Day 1 and Day 6, 0-72 hours post-dose

07

Study locations

1 site
  • The First Affiliated Hospital of Soochow University
    Suzhou, Jiangsu 215000, China
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jul 2020 to primary completion in Aug 2020, 0 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 13, 2021
First posted
Jan 15, 2021
StartActual
Jul 30, 2020
Primary completionActual
Aug 16, 2020
CompletionActual
Aug 21, 2020
Last update
May 11, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 11, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04712500
Lead sponsor
Kind Pharmaceuticals LLC
Responsible party
Sponsor
First posted
Jan 15, 2021
Start date
Jul 30, 2020
Primary completion
Aug 16, 2020
Completion
Aug 21, 2020
Last update
May 11, 2021

Study contacts

Yusha Zhu, MD PhD
study director · Kind Pharmaceuticals LLC

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: AND017

Start the discussion